ARA-290 (Cibinetide) – 16mg

Description

Innate Repair Receptor Peptide for Neurological Recovery, Inflammation Modulation & Tissue Protection

What Is It? (Background)

ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide engineered from the structure of erythropoietin (EPO). Unlike EPO, ARA-290 was specifically designed to activate tissue-protective pathways without stimulating red blood cell production, avoiding many of the hematologic risks associated with EPO therapy.

ARA-290 selectively targets the Innate Repair Receptor (IRR), a receptor complex that becomes activated during tissue injury, inflammation, metabolic stress, and nerve damage. Research has focused heavily on its potential role in:

Small fiber neuropathy

Chronic inflammation

Nerve regeneration

Tissue repair signaling

Metabolic dysfunction

Because of its unique mechanism, ARA-290 is often classified as a tissue-protective and regenerative peptide rather than a traditional growth factor or pain medication.

What Does It Do?

ARA-290 is studied for its ability to support:

• Nerve repair and regeneration
• Reduction of chronic inflammatory signaling
• Neuropathic pain relief
• Tissue protection during injury or metabolic stress
• Improved nerve fiber density and function
• Recovery from inflammatory tissue damage

Unlike many compounds that simply suppress symptoms, ARA-290 is being investigated for its ability to promote an environment of repair and restoration.

How Does It Function in the Body?

1. Innate Repair Receptor (IRR) Activation

ARA-290 selectively activates the Innate Repair Receptor, a heteromeric receptor composed of:

Erythropoietin receptor (EPOR)

β-common receptor (CD131)

This receptor is upregulated during:

• Injury
• Inflammation
• Cellular stress

Activation promotes tissue protection and repair signaling without erythropoietic effects.

2. Anti-Inflammatory Signaling

Research suggests ARA-290:

• Reduces pro-inflammatory cytokine activity
• Suppresses excessive neuroinflammatory responses
• Helps shift tissues from a damage state toward recovery

This mechanism appears particularly relevant in neuropathic and inflammatory conditions.

3. Nerve Fiber Regeneration

ARA-290 has demonstrated the ability to support:

• Small nerve fiber repair
• Corneal nerve fiber regeneration
• Improved sensory nerve function

Clinical studies observed increases in corneal nerve fiber density alongside symptom improvement in neuropathy patients.

4. Cellular Protection & Recovery

Activation of the IRR initiates pathways associated with:

• Tissue protection
• Cellular survival signaling
• Repair of damaged tissues

Rather than functioning as a direct analgesic, ARA-290 appears to address underlying inflammatory and repair mechanisms.

What Do Studies Show?

Human and preclinical studies have reported:

Significant improvements in neuropathic symptoms in patients with small fiber neuropathy and sarcoidosis-associated nerve damage.

Increased corneal nerve fiber density, suggesting regenerative activity on damaged small nerve fibers.

Improvements in neuropathic pain and reductions in neuroinflammatory signaling in animal models.

Improved metabolic markers, including HbA1c and lipid profiles, in patients with type 2 diabetes and neuropathy.

Favorable safety findings without the hematologic effects typically associated with erythropoietin-based therapies.

Overall Benefits

Based on current research, ARA-290 is commonly positioned to support:

• Neuropathic pain reduction
• Small fiber nerve regeneration
• Tissue protection and recovery
• Reduced inflammatory signaling
• Improved cellular repair mechanisms
• Enhanced neurological resilience
• Metabolic support in inflammatory conditions